comprehensive -WSS

comprehensive

author：focus 2025-10-01 22:58:59 - browse：491

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Paying for Covid pills will soon shift to insurers

entertainment

focus

WSS

FDA has safety concerns on CRISPR

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Meta's Zuckerberg and Chan on track to put $50 billion into science

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

First Opinion Podcast: How to protect health care in times of war

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

explore

comprehensive

entertainment

Virginia high school admissions case could be legal follow

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

23andMe had bad news about my health. I wish a person had delivered it

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Medical leaders decry Supreme Court decision on affirmative action

CDC recommends rationing of RSV shot due to shortages

United colonoscopy coverage change 'may cost lives,' doctors say

Moderna hits safety problems in bold bid to reinvent medicine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why workplace violence is so common in health care

hotspot

Diversifying clinical trials isn't enough to close racial gaps: study

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Readout Newsletter: New research from Sanofi, Regeneron, etc.

First Opinion Podcast: How to protect health care in times of war

WHO may add ‘noma' to its list of neglected tropical diseases

'The Exorcist' director William Friedkin dead at 87

hotspot

entertainment

focus

entertainment